switching between glp-1 agonists glp 1 TrimRX Mechanisms by which GLP-1 agonists
Description
Conclusion Clinical trial data from large, controlled studies demonstrate the efficacy and safety of GLP-1 agonists in terms of A1C reduction, beneficial effects on body weight, and a low risk for hypoglycemic events when used as monotherapy
Conflict of interest Author MB was employed by Azevan Pharmaceuticals Inc
Yuan Y, Yan Z, Lao Q, Jiang N, Wu S, Lu Q, et al
Blue Cross announced Thursday that starting on January 1, 2026, standard coverage plans will not cover GLP-1s for weight loss
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease
When making these types of decisions, its essential to take a holistic approach to addressing these healthcare trends as an organization
